Esperion Therapeutics, Inc. (ESPR) Bundle
Understanding Esperion Therapeutics, Inc. (ESPR) Revenue Streams
Understanding Esperion Therapeutics, Inc.’s Revenue Streams
Product Sales, Net:
For the nine months ended September 30, 2024, product sales, net totaled $84.2 million, compared to $57.6 million for the same period in 2023, reflecting an increase of $26.6 million. For the three months ended September 30, 2024, product sales, net were $31.1 million, up from $20.3 million in 2023, a rise of approximately $10.8 million.
Collaboration Revenue:
Collaboration revenue for the nine months ended September 30, 2024 was $179.0 million compared to $26.5 million in 2023, representing an increase of $152.5 million. In the three months ended September 30, 2024, collaboration revenue was $20.5 million, up from $13.7 million in 2023, an increase of $6.8 million.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for product sales from 2023 to 2024 is 46.2% for the nine-month period and approximately 53.3% for the third quarter. The collaboration revenue growth rate is 575.3% for the nine-month period and approximately 49.6% for the third quarter.
Contribution of Different Business Segments to Overall Revenue
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | 9M 2024 Revenue | 9M 2023 Revenue | Percentage Contribution (9M 2024) |
|---|---|---|---|---|---|
| Product Sales, Net | $31.1 million | $20.3 million | $84.2 million | $57.6 million | 31.9% |
| Collaboration Revenue | $20.5 million | $13.7 million | $179.0 million | $26.5 million | 68.1% |
Analysis of Significant Changes in Revenue Streams
The substantial increase in collaboration revenue can be attributed to the revenue recognized from the Settlement Agreement with DSE and enhanced product sales to collaboration partners. The growth in product sales is primarily due to the increased prescription volumes of NEXLETOL and NEXLIZET following recent label expansions and marketing efforts.
Furthermore, the cost of goods sold for the nine months ended September 30, 2024, was $43.0 million, compared to $31.8 million for the same period in 2023, indicating a rise of $11.2 million due to higher sales volumes.
The overall revenue growth reflects the company's strategic focus on expanding its market presence and enhancing product offerings, which have resulted in increased demand and sales.
A Deep Dive into Esperion Therapeutics, Inc. (ESPR) Profitability
A Deep Dive into Esperion Therapeutics, Inc. Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was calculated as follows:
| Metric | Value (2024) | Value (2023) |
|---|---|---|
| Product Sales, Net | $84,164,000 | $57,575,000 |
| Cost of Goods Sold | $42,970,000 | $31,815,000 |
| Gross Profit | $41,194,000 | $25,760,000 |
| Gross Profit Margin (%) | 48.9% | 44.8% |
Operating Profit Margin: The operating profit margin for the nine months ended September 30, 2024, was:
| Metric | Value (2024) | Value (2023) |
|---|---|---|
| Income (Loss) from Operations | $58,822,000 | ($113,196,000) |
| Total Revenue | $263,201,000 | $84,084,000 |
| Operating Profit Margin (%) | 22.3% | (134.6%) |
Net Profit Margin: The net profit margin for the nine months ended September 30, 2024, was:
| Metric | Value (2024) | Value (2023) |
|---|---|---|
| Net Loss | ($30,427,000) | ($152,904,000) |
| Total Revenue | $263,201,000 | $84,084,000 |
| Net Profit Margin (%) | (11.6%) | (181.7%) |
Trends in Profitability Over Time
Gross Profit: The gross profit increased significantly from $25.8 million in 2023 to $41.2 million in 2024, reflecting a positive trend in product sales growth.
Operating Income: The shift from a loss of $113.2 million in 2023 to a profit of $58.8 million in 2024 indicates a substantial improvement in operational efficiency and revenue generation.
Net Loss Reduction: The net loss decreased from $152.9 million in 2023 to $30.4 million in 2024, highlighting improved financial health.
Comparison of Profitability Ratios with Industry Averages
The industry average for gross profit margin in the biotechnology sector is approximately 70%. The current gross profit margin of 48.9% is below the industry average, indicating potential areas for improvement in cost management.
The operating profit margin in the biotech industry typically ranges from 10% to 20%. At 22.3%, the company is within this range, showcasing effective cost control relative to peers.
Net profit margins in the industry are often negative due to high R&D costs, but a margin of (11.6%) is an improvement compared to the prior year, signaling a potential return to profitability.
Analysis of Operational Efficiency
Cost Management: Operating expenses rose to $204.4 million in 2024 from $197.3 million in 2023. However, the significant increase in revenue outpaced the growth in expenses, leading to improved profitability metrics.
Gross Margin Trends: The increase in gross profit margin from 44.8% to 48.9% indicates better pricing strategies and cost efficiencies in production.
Research and Development Expenses: R&D expenses decreased from $68.4 million in 2023 to $35.3 million in 2024, contributing positively to the bottom line while still supporting innovation.
Conclusion
The profitability metrics for the nine months ended September 30, 2024, demonstrate significant improvements across various dimensions, with gross profit, operating profit, and net profit margins showing promising trends.
Debt vs. Equity: How Esperion Therapeutics, Inc. (ESPR) Finances Its Growth
Debt vs. Equity: How Esperion Therapeutics Finances Its Growth
As of September 30, 2024, the total liabilities of the company amounted to $684.3 million, with $265.0 million attributed to convertible notes and $304.7 million from a royalty sale liability.
Overview of the Company's Debt Levels
The company’s debt structure includes:
- Long-term Debt: Convertible notes totaling $265.0 million.
- Royalty Sale Liability: $304.7 million as of September 30, 2024.
- Short-term Debt: Various accrued liabilities totaling $19.2 million.
Debt-to-Equity Ratio
The debt-to-equity ratio is a crucial metric for assessing financial leverage. As of September 30, 2024, the company reported:
- Total Stockholders' Deficit: ($370.2 million)
- Debt-to-Equity Ratio: Calculated as 684.3 million / (370.2 million) = -1.85.
Comparison to Industry Standards
Comparatively, the average debt-to-equity ratio in the biopharmaceutical industry typically ranges from 0.5 to 1.5. The company's negative ratio indicates a reliance on debt financing over equity.
Recent Debt Issuances and Refinancing Activity
Recent activities include:
- On June 27, 2024, the company repurchased revenue interests for $343.8 million, resulting in a loss on extinguishment of debt of $53.2 million.
- In January 2024, the company raised approximately $90.7 million through an offering of common stock.
Credit Ratings
The company has not publicly disclosed a credit rating as of September 30, 2024, but its substantial debt levels and operating losses may affect its creditworthiness.
Balancing Between Debt Financing and Equity Funding
To manage its financial health, the company has employed a mix of financing strategies:
- Utilized $70.0 million from at-the-market equity offerings to bolster liquidity.
- Engaged in convertible note issuances to access capital while minimizing immediate cash outflows.
Table: Summary of Debt and Equity Structure
| Type | Amount (in millions) |
|---|---|
| Convertible Notes | $265.0 |
| Royalty Sale Liability | $304.7 |
| Short-term Debt | $19.2 |
| Total Liabilities | $684.3 |
| Total Stockholders' Deficit | ($370.2) |
| Debt-to-Equity Ratio | -1.85 |
Assessing Esperion Therapeutics, Inc. (ESPR) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio, a measure of liquidity, is calculated as current assets divided by current liabilities. As of September 30, 2024, the current assets totaled $307.6 million, while current liabilities amounted to $165.9 million. This results in a current ratio of approximately 1.85. The quick ratio, which excludes inventories from current assets, is calculated as follows:
Quick Assets = Current Assets - Inventories
Quick Assets = $307.6 million - $80.1 million = $227.5 million
Quick Ratio = Quick Assets / Current Liabilities = $227.5 million / $165.9 million ≈ 1.37
Analysis of Working Capital Trends
Working capital is calculated as current assets minus current liabilities. As of September 30, 2024, working capital is:
Working Capital = Current Assets - Current Liabilities = $307.6 million - $165.9 million = $141.7 million
This demonstrates a significant improvement from the previous year, reflecting better liquidity management and operational efficiency.
Cash Flow Statements Overview
Operating Cash Flow
Net cash provided by operating activities for the nine months ended September 30, 2024, was $11.3 million, a stark contrast to the cash used in operating activities of $(98.4 million) for the same period in 2023.
Investing Cash Flow
Net cash used in investing activities for the nine months ended September 30, 2024, was $(0.3 million), compared to net cash provided by investing activities of $42.5 million during the same period in 2023.
Financing Cash Flow
Net cash provided by financing activities for the nine months ended September 30, 2024, was $51.5 million, up from $46.0 million for the nine months ended September 30, 2023.
| Cash Flow Component | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by (used in) operating activities | $11,298 | $(98,431) |
| Net cash (used in) provided by investing activities | $(317) | $42,500 |
| Net cash provided by financing activities | $51,488 | $45,989 |
| Net increase (decrease) in cash and cash equivalents | $62,469 | $(9,942) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported cash and cash equivalents of $144.7 million, indicating a solid liquidity position. However, the company has a significant accumulated deficit of $(1.58 billion), which could pose long-term risks to liquidity if not managed effectively. The ongoing operational losses, which totaled $(30.4 million) for the nine months ended September 30, 2024, indicate that continuous funding may be necessary to support operations and growth initiatives.
Is Esperion Therapeutics, Inc. (ESPR) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the financial metrics for valuation analysis are as follows:
- Price-to-Earnings (P/E) Ratio: Not applicable, as the company reported a net loss of $30.4 million for the nine months ended September 30, 2024 .
- Price-to-Book (P/B) Ratio: The book value per share is approximately $1.63, with total stockholders' equity at a deficit of $370.2 million .
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Not applicable due to negative EBITDA .
The stock price trends over the last 12 months have shown significant volatility. The stock price was approximately $1.50 per share following the January 2024 offering . Over the past year, the stock has fluctuated between highs of about $3.50 and lows around $0.90, reflecting market reactions to product sales and financial results .
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, and thus the dividend yield is 0%. The payout ratio is also not applicable due to the absence of dividends and ongoing net losses .
Analyst Consensus on Stock Valuation
Analyst consensus ratings reflect a cautious outlook, with the majority advising a hold rating. The estimated price target ranges from $1.00 to $2.00 per share, indicating potential for slight upside from current levels .
| Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | N/A |
| Price-to-Book (P/B) Ratio | 1.63 |
| Enterprise Value-to-EBITDA (EV/EBITDA) Ratio | N/A |
| Stock Price (as of January 2024) | $1.50 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
| Estimated Price Target Range | $1.00 - $2.00 |
Key Risks Facing Esperion Therapeutics, Inc. (ESPR)
Key Risks Facing Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. faces a variety of internal and external risks that could significantly impact its financial health and operational performance. Below are the key risk factors identified:
Industry Competition
The pharmaceutical industry is characterized by intense competition, particularly in the market for cholesterol-lowering medications. As of September 30, 2024, the company reported $31.1 million in product sales, up from $20.3 million in the same quarter of the previous year, reflecting growth despite competitive pressures.
Regulatory Changes
Changes in regulatory policies or delays in obtaining necessary approvals can adversely affect the company’s ability to market its products. The company has continuously navigated regulatory environments, with recent approvals for expanded indications for its products in March 2024.
Market Conditions
Fluctuations in market conditions, including economic downturns or changes in healthcare policies, can affect sales. The company’s collaboration revenue increased significantly to $20.5 million in Q3 2024 from $13.7 million in Q3 2023, highlighting its ability to adapt but also exposing it to broader market risks.
Operational Risks
Operational risks include potential disruptions in manufacturing or supply chain issues. The cost of goods sold increased to $17.3 million in Q3 2024 from $13.4 million in Q3 2023, indicating rising operational costs.
Financial Risks
As of September 30, 2024, the company reported a total net loss of $30.4 million for the nine months ended September 30, 2024, compared to a loss of $152.9 million in the previous year, demonstrating ongoing financial challenges. The company also reported interest expenses of $42.8 million for the same period.
Strategic Risks
Strategic risks arise from the company’s reliance on a narrow product portfolio. The loss on extinguishment of debt for the nine months ended September 30, 2024, was $53.2 million, a significant factor that could impact future strategic decisions.
Mitigation Strategies
The company has taken steps to mitigate these risks, including entering into collaboration agreements, which contributed significantly to revenue. As of September 30, 2024, total liabilities stood at $684.3 million, up from $660.8 million at the end of 2023, indicating a strategic focus on managing financial obligations.
| Risk Factor | Description | 2024 Financial Impact |
|---|---|---|
| Industry Competition | Intense competition in cholesterol-lowering market | Product sales increased to $31.1 million |
| Regulatory Changes | Changes in policies affecting market access | Expansion of product indications approved |
| Market Conditions | Fluctuating economic conditions affecting sales | Collaboration revenue increased to $20.5 million |
| Operational Risks | Potential disruptions in manufacturing | Cost of goods sold rose to $17.3 million |
| Financial Risks | High net loss and interest expenses | Net loss of $30.4 million; interest expense $42.8 million |
| Strategic Risks | Reliance on a narrow product portfolio | Loss on extinguishment of debt: $53.2 million |
Future Growth Prospects for Esperion Therapeutics, Inc. (ESPR)
Future Growth Prospects for Esperion Therapeutics, Inc.
Analysis of Key Growth Drivers
Key growth drivers for Esperion Therapeutics include product innovations, market expansions, and strategic partnerships. The company's lead products, NEXLETOL and NEXLIZET, have shown significant prescription growth, with product sales, net reaching $31.1 million for the three months ended September 30, 2024, compared to $20.3 million for the same period in 2023, marking an increase of approximately $10.8 million.
Collaboration revenue has also seen a substantial increase, rising to $20.5 million in Q3 2024 from $13.7 million in Q3 2023, an increase of $6.8 million. This growth is attributed to increased royalty sales within partner territories and product sales to collaboration partners.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenues reached $263.2 million, a significant increase from $84.1 million in the same period for 2023. Product sales, net for the nine months ended September 30, 2024, were $84.2 million, up from $57.6 million in 2023, indicating a growth of $26.6 million.
The operating income for the nine months ended September 30, 2024, was reported at $58.8 million, a remarkable turnaround from a loss of $113.2 million in the same period of 2023. Analysts anticipate that continued commercialization efforts and expanded product indications could lead to further revenue growth in the coming years.
Strategic Initiatives or Partnerships that May Drive Future Growth
Esperion has engaged in significant collaborations, including a Royalty Purchase Agreement with OMERS, which generated $304.7 million in June 2024. Additionally, the company entered a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell up to $70 million of shares, enhancing liquidity for future initiatives.
In terms of market expansion, the company plans to file supplemental New Drug Applications in Canada in Q4 2024 and in Australia and Israel in H1 2025. This strategic focus on international markets is expected to contribute positively to revenue streams.
Competitive Advantages that Position the Company for Growth
Esperion's competitive advantages include a strong pipeline of innovative non-statin therapies targeting LDL-C reduction and cardiovascular risk. The FDA's expanded indications for NEXLETOL and NEXLIZET in March 2024 further enhance their marketability. The completed Phase 3 CLEAR Outcomes trial demonstrated a significant 21.1% placebo-corrected LDL-C lowering, supporting the efficacy of these products in high-risk patients.
The company's ability to generate net cash from operations, which totaled $11.3 million for the nine months ended September 30, 2024, compared to cash used of $98.4 million in the same period of 2023, showcases a positive trend in operational efficiency.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Product Sales, Net | $31.1 Million | $20.3 Million | $10.8 Million |
| Collaboration Revenue | $20.5 Million | $13.7 Million | $6.8 Million |
| Total Revenues (Nine Months) | $263.2 Million | $84.1 Million | $179.1 Million |
| Operating Income (Nine Months) | $58.8 Million | Loss of $113.2 Million | $172.0 Million |
| Net Cash from Operations | $11.3 Million | Loss of $98.4 Million | $109.7 Million |
Esperion Therapeutics, Inc. (ESPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Esperion Therapeutics, Inc. (ESPR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Esperion Therapeutics, Inc. (ESPR)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Esperion Therapeutics, Inc. (ESPR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.